Observational Study in Patients With Nail Psoriasis Treated With Enstilar® to Assess the Severity Change and the Quality of Life
NCT ID: NCT04380597
Last Updated: 2021-08-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
10 participants
OBSERVATIONAL
2019-03-26
2021-07-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study Evaluating the Efficacy and Tolerability of Enstilar Foam in Patients With Nail Psoriasis
NCT04227288
Efficacy and Tolerability of Enstilar® in Daily Practice
NCT02881346
To Study Generic Calcipotriene and Betamethasone Dipropionate Topical Foam, 0.005%/0.064%, in the Treatment of Psoriasis Vulgaris (Plaque Psoriasis).
NCT03731091
Assessing the Efficacy of Image-guided Laser-assisted Enstilar® Delivery for Treatment of Psoriatic Nails
NCT04580537
Enstilar® Foam in the Treatment of Chronic Plaque Psoriasis in Patients With Skin of Color
NCT03506477
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients with nail psoriasis
Patients with nail psoriasis who are prescribed, according to clinical practice, a topical treatment with calcipotriene and betamethasone dipropionate aerosol foam.
Calcipotriene and betamethasone dipropionate aerosol foam
Prescribed according to clinical practice and following Product Data Sheet instructions
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Calcipotriene and betamethasone dipropionate aerosol foam
Prescribed according to clinical practice and following Product Data Sheet instructions
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients who authorize their participation in the study by signing written informed consent.
Exclusion Criteria
* Patients with any situation or state that in the opinion of the investigator discourages their participation in the study.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Angeles Florez
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Angeles Florez
Head of Dermatology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Complejo Hospitalario Universitario de Pontevedra
Pontevedra, , Spain
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ENUPS
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.